In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Alx Oncology Holdings Inc (NASDAQ: ALXO) closed at $1.36 down -2.86% from its previous closing price of $1.4. In other words, the price has decreased by -$2.86 from its previous closing price. On the day, 69963.0 shares were traded. ALXO stock price reached its highest trading level at $1.42 during the session, while it also had its lowest trading level at $1.35.
Ratios:
For a deeper understanding of Alx Oncology Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on November 13, 2025, initiated with a Buy rating and assigned the stock a target price of $4.
On March 06, 2025, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $3.
Jefferies Downgraded its Buy to Hold on December 19, 2024, whereas the target price for the stock was revised from $12 to $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 17 ’25 when Lettmann Jason bought 71,163 shares for $1.08 per share. The transaction valued at 76,892 led to the insider holds 305,121 shares of the business.
Lettmann Jason bought 21,070 shares of ALXO for $22,461 on Sep 16 ’25. The CHIEF EXECUTIVE OFFICER now owns 233,958 shares after completing the transaction at $1.07 per share. On Aug 18 ’25, another insider, Shantharam Harish, who serves as the Chief Financial Officer of the company, bought 75,000 shares for $0.78 each. As a result, the insider paid 58,402 and bolstered with 75,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALXO now has a Market Capitalization of 73736480 and an Enterprise Value of 28717482.
Stock Price History:
The Beta on a monthly basis for ALXO is 0.50, which has changed by -0.17159766 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, ALXO has reached a high of $2.27, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is -6.93%, while the 200-Day Moving Average is calculated to be 43.79%.
Shares Statistics:
For the past three months, ALXO has traded an average of 401.37K shares per day and 153620 over the past ten days. A total of 53.58M shares are outstanding, with a floating share count of 38.41M. Insiders hold about 29.16% of the company’s shares, while institutions hold 34.42% stake in the company. Shares short for ALXO as of 1764288000 were 793867 with a Short Ratio of 2.61, compared to 1761868800 on 1844412. Therefore, it implies a Short% of Shares Outstanding of 793867 and a Short% of Float of 2.31.
Earnings Estimates
The performance of Alx Oncology Holdings Inc (ALXO) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$1.56 and -$1.56 for the fiscal current year, implying an average EPS of -$1.56. EPS for the following year is -$0.75, with 1.0 analysts recommending between -$0.75 and -$0.75.
